{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T02:22:03Z","timestamp":1789006923557,"version":"build-2803163510"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2015,7,31]],"date-time":"2015-07-31T00:00:00Z","timestamp":1438300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,7,31]],"date-time":"2015-07-31T00:00:00Z","timestamp":1438300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Obes"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1038\/ijo.2015.136","type":"journal-article","created":{"date-parts":[[2015,7,31]],"date-time":"2015-07-31T03:50:00Z","timestamp":1438314600000},"page":"1651-1654","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Transfer of liraglutide from blood to cerebrospinal fluid is minimal in patients with type 2 diabetes"],"prefix":"10.1038","volume":"39","author":[{"given":"M","family":"Christensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A H","family":"Sparre-Ulrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U","family":"Grevstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M M","family":"Rosenkilde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J J","family":"Holst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Vilsb\u00f8ll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F K","family":"Knop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,7,31]]},"reference":[{"key":"BFijo2015136_CR1","unstructured":"Saxenda.com. Available at: https:\/\/www.saxenda.com\/ (accessed on 15 April 2015)."},{"key":"BFijo2015136_CR2","doi-asserted-by":"publisher","first-page":"T1","DOI":"10.1530\/JOE-13-0414","volume":"221","author":"L Van Bloemendaal","year":"2014","unstructured":"Van Bloemendaal L, Ten Kulve JS, la Fleur SE, Ijzerman RG, Diamant M . Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. J Endocrinol 2014; 221: T1\u2013T16.","journal-title":"J Endocrinol"},{"key":"BFijo2015136_CR3","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/379069a0","volume":"379","author":"MD Turton","year":"1996","unstructured":"Turton MD, O\u2019Shea D, Gunn I, Beak SA, Edwards CM, Meeran K et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996; 379: 69\u201372.","journal-title":"Nature"},{"key":"BFijo2015136_CR4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-2202-13-33","volume":"13","author":"K Hunter","year":"2012","unstructured":"Hunter K, H\u00f6lscher C . Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci 2012; 13: 33.","journal-title":"BMC Neurosci"},{"key":"BFijo2015136_CR5","doi-asserted-by":"publisher","first-page":"6587","DOI":"10.1523\/JNEUROSCI.0529-11.2011","volume":"31","author":"PL McClean","year":"2011","unstructured":"McClean PL, Parthsarathy V, Faivre E, H\u00f6lscher C . The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer\u2019s disease. J Neurosci 2011; 31: 6587\u20136594.","journal-title":"J Neurosci"},{"key":"BFijo2015136_CR6","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/sj.ijo.0802206","volume":"27","author":"AJ Kastin","year":"2003","unstructured":"Kastin AJ, Akerstrom V . Entry of exendin-4 into brain is rapid but may be limited at high doses. Int J Obes Relat Metab Disord 2003; 27: 313\u2013318.","journal-title":"Int J Obes Relat Metab Disord"},{"key":"BFijo2015136_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1385\/JMN:18:1-2:07","volume":"18","author":"AJ Kastin","year":"2002","unstructured":"Kastin AJ, Akerstrom V, Pan W . Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J Mol Neurosci 2002; 18: 7\u201314.","journal-title":"J Mol Neurosci"},{"key":"BFijo2015136_CR8","doi-asserted-by":"publisher","first-page":"4473","DOI":"10.1172\/JCI75276","volume":"124","author":"A Secher","year":"2014","unstructured":"Secher A, Jelsing J, Baquero AF, Hecksher-S\u00f8rensen J, Cowley MA, Dalb\u00f8ge LS et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest 2014; 124: 4473\u20134488.","journal-title":"J Clin Invest"},{"key":"BFijo2015136_CR9","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.1002\/cne.23355","volume":"521","author":"F Langlet","year":"2013","unstructured":"Langlet F, Mullier A, Bouret SG, Prevot V, Dehouck B . Tanycyte-like cells form a blood-cerebrospinal fluid barrier in the circumventricular organs of the mouse brain. J Comp Neurol 2013; 521: 3389\u20133405.","journal-title":"J Comp Neurol"},{"key":"BFijo2015136_CR10","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1677\/joe.0.1720355","volume":"172","author":"CF Deacon","year":"2002","unstructured":"Deacon CF, Wamberg S, Bie P, Hughes TE, Holst JJ . Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. J Endocrinol 2002; 172: 355\u2013362.","journal-title":"J Endocrinol"},{"key":"BFijo2015136_CR11","doi-asserted-by":"publisher","first-page":"535","DOI":"10.2337\/diab.43.4.535","volume":"43","author":"C \u00d8rskov","year":"1994","unstructured":"\u00d8rskov C, Rabenh\u00f8j L, Wettergren A, Kofod H, Holst JJ . Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 1994; 43: 535\u2013539.","journal-title":"Diabetes"},{"key":"BFijo2015136_CR12","doi-asserted-by":"publisher","first-page":"832","DOI":"10.2337\/diab.45.6.832","volume":"45","author":"C \u00d8rskov","year":"1996","unstructured":"\u00d8rskov C, Poulsen SS, M\u00f8ller M, Holst JJ . Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I. Diabetes 1996; 45: 832\u2013835.","journal-title":"Diabetes"},{"key":"BFijo2015136_CR13","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.physbeh.2007.04.003","volume":"91","author":"M Fry","year":"2007","unstructured":"Fry M, Ferguson AV . The sensory circumventricular organs: brain targets for circulating signals controlling ingestive behavior. Physiol Behav 2007; 91: 413\u2013423.","journal-title":"Physiol Behav"},{"key":"BFijo2015136_CR14","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.autneu.2003.11.001","volume":"110","author":"A Nakagawa","year":"2004","unstructured":"Nakagawa A, Satake H, Nakabayashi H, Nishizawa M, Furuya K, Nakano S et al. Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells. Auton Neurosci 2004; 110: 36\u201343.","journal-title":"Auton Neurosci"},{"key":"BFijo2015136_CR15","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.nbd.2009.09.025","volume":"37","author":"MS Alavijeh","year":"2010","unstructured":"Alavijeh MS, Palmer AM . Measurement of the pharmacokinetics and pharmacodynamics of neuroactive compounds. Neurobiol Dis 2010; 37: 38\u201347.","journal-title":"Neurobiol Dis"},{"key":"BFijo2015136_CR16","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/j.addr.2004.07.011","volume":"56","author":"DD Shen","year":"2004","unstructured":"Shen DD, Artru AA, Adkison KK . Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics. Adv Drug Deliv Rev 2004; 56: 1825\u20131857.","journal-title":"Adv Drug Deliv Rev"}],"container-title":["International Journal of Obesity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/ijo2015136.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/ijo2015136","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/ijo2015136.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T15:33:18Z","timestamp":1647358398000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ijo2015136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,31]]},"references-count":16,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["BFijo2015136"],"URL":"https:\/\/doi.org\/10.1038\/ijo.2015.136","relation":{},"ISSN":["0307-0565","1476-5497"],"issn-type":[{"value":"0307-0565","type":"print"},{"value":"1476-5497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,31]]},"assertion":[{"value":"2 January 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JJH has served as a consultant or advisor to: Novartis Pharmaceuticals, Novo Nordisk, Merck, Sharp and Dome and Roche. JJH has received fees for speaking from Novo Nordisk, Merck, Sharp and Dome and GSK. TV has received fees for consulting, lecturing and\/or being part of an advisory board from: AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly, GI Dynamics, Merck Sharp & Dohme, Novo Nordisk, Novartis, Sanofi, Takeda and Zealand Pharma. TV has received research support from Novo Nordisk. FKK has received fees for consulting, lecturing and\/or being part of an advisory board from: AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly, Gilead Sciences, Merck Sharp & Dohme, Novartis, Novo Nordisk, Ono Pharmaceuticals, Sanofi, Zealand Pharma. FKK has received research support from Sanofi and Novo Nordisk. The remaining authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}